eli lilly glp-1 advantage decreasing FDA approves new weight-loss pill, Foundayo Eli Lilly vs Novo Nordisk:

[DOI] [PubMed] [Google Scholar] 71.Dupre J., Ross S.A., Watson D., Brown J.C

Increased volume of distribution, particularly in individuals with higher adipose tissue mass and elevated expression of Kruppel-like factor 4, may alter drug metabolism and clearance rates

The dose-dependent effect of GLP-1 on decelerating gastric emptying plays a substantial role in improving postprandial glycemic concentrations to the extent that postprandial insulin secretion may no longer be stimulated or could even be reduced (154, 155) ( Figure 1 Section D)

Switching to an oral pill may appeal to those who dislike injections or want a simpler dosing routine, while a lower injectable dose may offer a cheaper option that may also result in less adverse events

muciniphila stimulates GLP-1 secretion and improves insulin sensitivity through multiple pathways, including both SCFA production and direct L-cell signaling

A common experience is "This increased dosage is killing me